
ETTX
Healthcare · Biotechnology · $104.8M market cap
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Jun 30, 2022
EPS trend, 90 days to now · -3.6% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 3 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Apr 27, 2022 | Before the open | -0.26 | -0.32 | -23.1% |
| Mar 3, 2022 | Before the open | -0.27 | -0.25 | +7.4% |
| Nov 4, 2021 | Before the open | -0.28 | -0.26 | +7.1% |
| Aug 11, 2021 | After the close | -0.32 | -0.29 | +9.4% |
| May 5, 2021 | After the close | -0.36 | -0.29 | +19.4% |
| Mar 23, 2021 | Before the open | -0.39 | -0.13 | +66.7% |
| Nov 5, 2020 | After the close | -0.50 | -0.37 | +26.0% |
| Aug 6, 2020 | After the close | -0.74 | -0.78 | -5.4% |
| May 7, 2020 | After the close | -1.00 | -1.15 | -15.0% |
| Mar 11, 2020 | After the close | -0.68 | -1.06 | -55.9% |
| Nov 14, 2019 | Before the open | -0.87 | -0.27 | +69.0% |
| Aug 12, 2019 | Before the open | -0.60 | -1.02 | -70.0% |
| May 14, 2019 | Before the open | -0.75 | -0.99 |
Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial products to treat serious infections caused by multidrug-resistant pathogens in the United States. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that is in Phase III clinical trial for the treatment of pneumonia and…
| -32.0% |
| Mar 29, 2019 | Before the open | -0.80 | -2.36 | -195.0% |
| Nov 14, 2018 | Before the open | -0.90 | -20.00 | -2122.2% |